Financhill
Buy
59

TGTX Quote, Financials, Valuation and Earnings

Last price:
$37.11
Seasonality move :
-16.42%
Day range:
$37.07 - $37.70
52-week range:
$16.65 - $46.48
Dividend yield:
0%
P/E ratio:
154.52x
P/S ratio:
15.43x
P/B ratio:
24.81x
Volume:
957.3K
Avg. volume:
1.7M
1-year change:
73.38%
Market cap:
$5.9B
Revenue:
$329M
EPS (TTM):
$0.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TGTX
TG Therapeutics
$145.3M $0.28 101.13% 653.48% $40.50
ALNY
Alnylam Pharmaceuticals
$641.1M -$0.01 -3.52% -58.59% $329.54
ARDX
Ardelyx
$82.5M -$0.14 12.93% -95.54% $10.73
BPMC
Blueprint Medicines
$171.3M -$0.53 24.15% -36.72% $126.87
RCEL
AVITA Medical
$22.4M -$0.23 47.51% -61.01% $16.95
RYTM
Rhythm Pharmaceuticals
$43.8M -$0.66 50.34% -12.27% $102.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TGTX
TG Therapeutics
$37.09 $40.50 $5.9B 154.52x $0.00 0% 15.43x
ALNY
Alnylam Pharmaceuticals
$314.94 $329.54 $41.1B -- $0.00 0% 17.24x
ARDX
Ardelyx
$4.49 $10.73 $1.1B -- $0.00 0% 2.94x
BPMC
Blueprint Medicines
$129.30 $126.87 $8.4B -- $0.00 0% 14.74x
RCEL
AVITA Medical
$5.70 $16.95 $150.7M -- $0.00 0% 2.07x
RYTM
Rhythm Pharmaceuticals
$86.70 $102.29 $5.5B -- $0.00 0% 39.10x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TGTX
TG Therapeutics
-- -0.654 -- 2.01x
ALNY
Alnylam Pharmaceuticals
89.88% 0.837 2.91% 2.84x
ARDX
Ardelyx
50.95% -0.143 12.88% 3.43x
BPMC
Blueprint Medicines
53.13% 2.692 6.79% 2.62x
RCEL
AVITA Medical
112.39% -0.697 19.27% 1.65x
RYTM
Rhythm Pharmaceuticals
-- 1.349 -- 2.97x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TGTX
TG Therapeutics
$105.3M $8.6M 11.64% 19.78% 10.12% -$28.7M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
ARDX
Ardelyx
$61.8M -$36.3M -19.51% -34.68% -45.91% -$38.8M
BPMC
Blueprint Medicines
$146.6M -$41.1M -23.09% -49.13% 12.78% -$56.3M
RCEL
AVITA Medical
$15.7M -$11.8M -102.9% -415.55% -68.15% -$10.5M
RYTM
Rhythm Pharmaceuticals
$29.1M -$47M -116.92% -116.92% -134.57% -$40.4M

TG Therapeutics vs. Competitors

  • Which has Higher Returns TGTX or ALNY?

    Alnylam Pharmaceuticals has a net margin of 4.19% compared to TG Therapeutics's net margin of -9.67%. TG Therapeutics's return on equity of 19.78% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TGTX
    TG Therapeutics
    87.14% $0.03 $237.3M
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About TGTX or ALNY?

    TG Therapeutics has a consensus price target of $40.50, signalling upside risk potential of 9.21%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $329.54 which suggests that it could grow by 4.64%. Given that TG Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe TG Therapeutics is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TGTX
    TG Therapeutics
    5 1 0
    ALNY
    Alnylam Pharmaceuticals
    13 7 1
  • Is TGTX or ALNY More Risky?

    TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.

  • Which is a Better Dividend Stock TGTX or ALNY?

    TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TGTX or ALNY?

    TG Therapeutics quarterly revenues are $120.9M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. TG Therapeutics's net income of $5.1M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, TG Therapeutics's price-to-earnings ratio is 154.52x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.43x versus 17.24x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TGTX
    TG Therapeutics
    15.43x 154.52x $120.9M $5.1M
    ALNY
    Alnylam Pharmaceuticals
    17.24x -- $594.2M -$57.5M
  • Which has Higher Returns TGTX or ARDX?

    Ardelyx has a net margin of 4.19% compared to TG Therapeutics's net margin of -55.52%. TG Therapeutics's return on equity of 19.78% beat Ardelyx's return on equity of -34.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    TGTX
    TG Therapeutics
    87.14% $0.03 $237.3M
    ARDX
    Ardelyx
    83.4% -$0.17 $297M
  • What do Analysts Say About TGTX or ARDX?

    TG Therapeutics has a consensus price target of $40.50, signalling upside risk potential of 9.21%. On the other hand Ardelyx has an analysts' consensus of $10.73 which suggests that it could grow by 138.92%. Given that Ardelyx has higher upside potential than TG Therapeutics, analysts believe Ardelyx is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TGTX
    TG Therapeutics
    5 1 0
    ARDX
    Ardelyx
    8 1 0
  • Is TGTX or ARDX More Risky?

    TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

  • Which is a Better Dividend Stock TGTX or ARDX?

    TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TGTX or ARDX?

    TG Therapeutics quarterly revenues are $120.9M, which are larger than Ardelyx quarterly revenues of $74.1M. TG Therapeutics's net income of $5.1M is higher than Ardelyx's net income of -$41.1M. Notably, TG Therapeutics's price-to-earnings ratio is 154.52x while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.43x versus 2.94x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TGTX
    TG Therapeutics
    15.43x 154.52x $120.9M $5.1M
    ARDX
    Ardelyx
    2.94x -- $74.1M -$41.1M
  • Which has Higher Returns TGTX or BPMC?

    Blueprint Medicines has a net margin of 4.19% compared to TG Therapeutics's net margin of 0.33%. TG Therapeutics's return on equity of 19.78% beat Blueprint Medicines's return on equity of -49.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    TGTX
    TG Therapeutics
    87.14% $0.03 $237.3M
    BPMC
    Blueprint Medicines
    98.13% $0.01 $729.9M
  • What do Analysts Say About TGTX or BPMC?

    TG Therapeutics has a consensus price target of $40.50, signalling upside risk potential of 9.21%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.88%. Given that TG Therapeutics has higher upside potential than Blueprint Medicines, analysts believe TG Therapeutics is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    TGTX
    TG Therapeutics
    5 1 0
    BPMC
    Blueprint Medicines
    2 15 1
  • Is TGTX or BPMC More Risky?

    TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

  • Which is a Better Dividend Stock TGTX or BPMC?

    TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TGTX or BPMC?

    TG Therapeutics quarterly revenues are $120.9M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. TG Therapeutics's net income of $5.1M is higher than Blueprint Medicines's net income of $496K. Notably, TG Therapeutics's price-to-earnings ratio is 154.52x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.43x versus 14.74x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TGTX
    TG Therapeutics
    15.43x 154.52x $120.9M $5.1M
    BPMC
    Blueprint Medicines
    14.74x -- $149.4M $496K
  • Which has Higher Returns TGTX or RCEL?

    AVITA Medical has a net margin of 4.19% compared to TG Therapeutics's net margin of -74.86%. TG Therapeutics's return on equity of 19.78% beat AVITA Medical's return on equity of -415.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    TGTX
    TG Therapeutics
    87.14% $0.03 $237.3M
    RCEL
    AVITA Medical
    84.7% -$0.53 $36.9M
  • What do Analysts Say About TGTX or RCEL?

    TG Therapeutics has a consensus price target of $40.50, signalling upside risk potential of 9.21%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 196.53%. Given that AVITA Medical has higher upside potential than TG Therapeutics, analysts believe AVITA Medical is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TGTX
    TG Therapeutics
    5 1 0
    RCEL
    AVITA Medical
    3 1 0
  • Is TGTX or RCEL More Risky?

    TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison AVITA Medical has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.797%.

  • Which is a Better Dividend Stock TGTX or RCEL?

    TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TGTX or RCEL?

    TG Therapeutics quarterly revenues are $120.9M, which are larger than AVITA Medical quarterly revenues of $18.5M. TG Therapeutics's net income of $5.1M is higher than AVITA Medical's net income of -$13.9M. Notably, TG Therapeutics's price-to-earnings ratio is 154.52x while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.43x versus 2.07x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TGTX
    TG Therapeutics
    15.43x 154.52x $120.9M $5.1M
    RCEL
    AVITA Medical
    2.07x -- $18.5M -$13.9M
  • Which has Higher Returns TGTX or RYTM?

    Rhythm Pharmaceuticals has a net margin of 4.19% compared to TG Therapeutics's net margin of -151.35%. TG Therapeutics's return on equity of 19.78% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    TGTX
    TG Therapeutics
    87.14% $0.03 $237.3M
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
  • What do Analysts Say About TGTX or RYTM?

    TG Therapeutics has a consensus price target of $40.50, signalling upside risk potential of 9.21%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $102.29 which suggests that it could grow by 17.98%. Given that Rhythm Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Rhythm Pharmaceuticals is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TGTX
    TG Therapeutics
    5 1 0
    RYTM
    Rhythm Pharmaceuticals
    10 0 0
  • Is TGTX or RYTM More Risky?

    TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.265, suggesting its more volatile than the S&P 500 by 126.541%.

  • Which is a Better Dividend Stock TGTX or RYTM?

    TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TGTX or RYTM?

    TG Therapeutics quarterly revenues are $120.9M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. TG Therapeutics's net income of $5.1M is higher than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, TG Therapeutics's price-to-earnings ratio is 154.52x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.43x versus 39.10x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TGTX
    TG Therapeutics
    15.43x 154.52x $120.9M $5.1M
    RYTM
    Rhythm Pharmaceuticals
    39.10x -- $32.7M -$49.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock